8/3/2019 Devanshu Final Ppt.1
1/45
BIOANALYTICAL METHOD DEVELOPMENT AND
VALIDATION FOR THE ESTIMATION OF MOXIFLOXACIN IN
HUMAN PLASMA USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY(LC-MS/MS)
Presented By:Devanshu Sharma
M.Pharm 2nd
yr(Pharmaceutics)MMU, Mullana.
1
Guide:
Dr. Anroop B Nair(Professor)
M.M College of Pharmacy
Co-Guide:
Dr. Sanjay Gurule(Group Leader)
Ranbaxy Research Laboratories
8/3/2019 Devanshu Final Ppt.1
2/45
1.Introduction
Bioanalysis is sub disciplined of analytical chemistry covering the
quantitative measurement of xenobiotics (drugs and their metabolites) in
biological system.
Bioanalytical method -set of all procedures involved in the collection,
processing, storing and analysis of biological matrix for an analyte.
LC-MS/MS is currently considered as a important analytical tool forquantitative analysis of drug(s) and metabolite(s) in biological fluids.
Method development involves evaluation and optimization of the various
stages of sample preparation, chromatographical separation, detection and
quantification.
Method validation includes all of the procedures required to demonstratethat a particular method is reliable for the intended application.
2
8/3/2019 Devanshu Final Ppt.1
3/45
2.Objective
The objective of this study is to establish a simple, accurate, rapid and
sensitive method using LC-MS/MS for the quantification of Moxifloxacin
in human plasma as per USFDA guidelines.
Supportive Objectives:
To select sample processing and extraction process for Moxifloxacin
extraction from human plasma. To select good column which will solve the problem of low response.
To select the appropriate mobile phase, reconstitution solution, rinsing
solution which will solve the problems of tailing of peak, carry over effect
respectively.
The developed and validated bio analytical method is used in performingbioequivalence study between the reference drug and generic drug
formulation.
3
8/3/2019 Devanshu Final Ppt.1
4/45
4
PLAN OF WORK
Identification of Drug.
Bio-analytical method development and validation.
Application of developed bio-analytical method to pharmacokinetic studies.
8/3/2019 Devanshu Final Ppt.1
5/45
Method Development
Method development is the setting up of an analytical procedure that will be appropriate for the
analysis of a particular sample.
Analytical strategy
The choice of method involves several considerations:
Which concentrations of the compound will be present in the samples?
What is the sample matrix?
What is the cost of the analysis?
Sample collection
Biological samples used in assays for the determination of drugs are often venous blood withdrawn
from the arm. The venous blood can be withdrawn into tubes with an anticoagulant, e.g. EDTA and
heparin. Both blood and plasma can be used for analysis.
Sample preparation Protein precipitation
Liquid-liquid extraction
Solid-phase extraction
5
8/3/2019 Devanshu Final Ppt.1
6/45
General method development steps include:-
a) Scanning
b) Optimization of LC-MS/MS parameter
c) Selection and optimization of mobile phase
d) Selection of column
e) Selection and optimization of sample
preparation method
6
8/3/2019 Devanshu Final Ppt.1
7/45
4. Drug profile
Fig. Molecular structure of Moxifloxacin
7
8/3/2019 Devanshu Final Ppt.1
8/45
Method Development
Scanning and Optimization on instrument
Stock of moxifloxacin and moxifloxacin d-4 (1mg/ml) and its two metabolites i.e moxifloxacin
acyl B-D glucuronide and moxifloxacin- n sulphate were weighed and dissolved in methanol
then for scanning of drug make dilution of drug 500ng/ml in (50:50) methanol and water.
Scanning of Moxifloxacin and Moxifloxacin d-4 was performed in +ve ion mode, m/z were
Moxifloxacin 402.2/358.3 and Moxifloxacin d-4 406.2/362.2 . Scanning and Optimization for
Moxifloxacin and Moxifloxacin d-4 was done in methanol: water (50:50). Each ions were
scanned at different m/z ratios .
Selection of column
Various columns selected for the analysis includes Discovery-C18 ,Ascentis-C18,Chromolith
performance were tried but less response and saturation in calibration curve was observed. But
in chromolith performance (100x4.6mm) there was good resolution as compared to other
columns used, desired retention time and symmetric peak shape was obtained .
8
Table : m/z ratio of ions of Moxifloxacin and Moxifloxacin d-4
m/z ratios Q1 scan (Parent) Q3 scan (Product)
Moxifloxacin 402.2 358.3
Moxifloxacind-4Moxifloxacin acyl-b-d glucuronideMoxifloxacin N-sulphate
406.2578.3482.2
362.2384.3402.3
8/3/2019 Devanshu Final Ppt.1
9/45
Detection
Mass spectrometer was used as a detector for the detection of the parent ion & product ion
according to their m/z values
MS detector consists of three main parts: the interface where the ions are generated, the mass
analyzer (separation) and the electron multiplier (detector)
The most popular ionization techniques are: electro spray ionization (ESI), atmospheric pressurechemical ionization (APCI)
The most common mass analyzers are: Triple quadrupole, ion-trap.
Selection of mobile phase
Various buffers (such as Ammonium Formate 1, 2,5mM) with 0.2% formic acid were made in
combination with Methanol and Acetonitrile in varying ratios (20:80, 30:70, 40:60) as a mobile
phase but there was a good chromatogram obtained in 5mM Ammonium formate(0.2% formicacid)-60:40-(Methanol).In Ammonium acetate there was a very bad peak shape with tailing
effect. Column chromloith performance was used which yielded good results. Then one P.A
batch was processed.
Selection of Internal standard
Compound with similarity in structure and physicochemical properties was tried as internal
standard which would give sufficient retention and stable response were obtained withmoxifloxacin d-4.
Selection of sample processing method
Solid Phase Extraction: Sample processing carried out by Solid Phase Extraction withBond Elute Plexa cartridges, using HPLC grade water (1ml) for washing twice and methanol
(1ml ) for elution(single) and centrifuge at 1500 rpm for 1 minute.
9
8/3/2019 Devanshu Final Ppt.1
10/45
6.Sample Extraction Procedure
10
8/3/2019 Devanshu Final Ppt.1
11/45
PREPARATION OF REAGENTS :-
Ammonium Formate buffer:Transferred 0.315g of ammonium formate into reagent bottleand added 1000ml of HPLC grade water and mixed well by sonicating in an ultrasonic bath to
get 5.0 0.1mM ammonium formate buffer solution. Adjust the pH to 2.600.1 with formic acid
Mobile phase:Transferred 600ml of Ammonium formate buffer into a 1000-mL reagentbottle, and added 400 mL of HPLC grade methanol.
Diluent-1:Transferred 500 mL of HPLC grade methanol into a 1000-mL reagent bottle andadded 500 mL of HPLC grade water.
Rinsing solution:500ml methanol+500 ml of HPLC grade water.
Preparation of internal standard solution (IS dilution) Weighed accurately Moxifloxacin d-4 internal standard and transferred into a volumetric flask.Dissolved in sufficient volume of methanol and made up the volume with the same to produce
1mg/mL of Moxifloxacin d-4. The stock solution was further diluted with methanol and water
(50:50) to get the final concentration of 2000ng/ml.
11
Preparation of Moxifloxacind-4 stock solution
Amt. Weighed (mg) 1
Volume made up to (ml) 1
Potency (%) 100
Mol wt of compound 441.92
Mol wt of Free compound N/AP
Calculated stock conc.(ng/ml)
1000000
Table : Preparation of Moxifloxacind-4 stock dilution
Stock Conc. Stock Aliquot Total Volume IS Dilution
(ng/mL) (mL) (mL) Conc. (ng/mL)
1000000 0.040 20 2000
8/3/2019 Devanshu Final Ppt.1
12/45
7. Optimized Chromatographic condition
Parameter Details
Column Chromolith Performance, RP-18,1004.6mm
Mobile Phase Methanol: Buffer-1** (40:60, v/v)
Reconstitution solution Methanol: Solution-1*(40:60, v/v)
Rinsing solution Methanol: HPLC grade water (50:50, v/v)
Flow Rate 1.2ml/minute
Split Ratio Approximately 0.400 ml mobile phase shouldgo to the ion source per minute
Sample cooler temperature 5C 1.0C
Column oven temperature 45C 1.0C
Injection Volume 10l
Retention time Moxifloxacin:1.40 to 2.40 minutesMoxifloxacin-d4:1.4 to 2.40 minutes
Ion source(polarity) Turbo-ion spray in positive ion mode
* Solution-1:Methanol: 500 ml hplc grade water with triethyl amine(.pH 10.5)
**Buffer-1:Methanol: Ammonium Formate (5mM,pH 2.60) 12
8/3/2019 Devanshu Final Ppt.1
13/45
8.Instrument specifications
Parameter Specification
Ion spray voltage 5500V
Temperature 450C
Curtain gas 8
Nebulizer gas 10Scanning mode Positive mode
Detection:
Moxifloxacin m/z 402.2 Q1(Mass) and 358.30 Q3
(Mass)
Moxifloxacin-d4 m/z 406.2 Q1(Mass) and 362.20 Q3
(Mass)13
8/3/2019 Devanshu Final Ppt.1
14/45
Stat file information for API 3000
Detection: Moxifloxacin m/z 402.2 / 358.3
Moxifloxacin d-4 m/z 406.2 / 362.2
14
Source Parameters of Moxifloxacin andMoxifloxacin d-4
Parameters Value
NC (Nebulizer
current)
10V
TEM(Temperature)
500C
CUR (Curtaingas)
08#
CAD 10#
# - these are typically values based on setting and scale defined insoftware application to control gas parameters
Compound Parameters of Moxifloxacin andMoxifloxacin d-4
Parameters Moxifloxacin Moxifloxacin d-4
DP (Declusteringpotential)
40V 40V
EP (Entrancepotential)
10V 10V
CE (Collisionenergy)
29V 29V
CXP (Collision cellexit potential)
25V 25V
8/3/2019 Devanshu Final Ppt.1
15/45
Preparation of Calibration Curve and quality controls Standard Preparation of standard stock solution of Moxifloxacin for CC:
Weighed accurately 1mg of moxifloxacin working standards and transferred into a 1mL
volumetric flask. Dissolved in sufficient volume of methanol and made up to the volume with
the same to produce 1mg/mL stock solution of moxifloxacin. Stored in refrigerator below 8 C.The stock solution was diluted to suitable concentrations using Diluent-1 for dilution for spiking
in plasma to obtain calibration curve (CC) standards.
15
Table : Preparation of moxifloxacin stocksolution
Amt. Weighed (mg) 1
Volume made up to (ml) 1
Potency (%) 100
Mol wt of compound 401.43
Free Mol wt of compound N/AP
Calculated stock conc.(ng/mL)
1000000
(
Table : Preparation of standard stock dilutions ofmoxifloxacin for CC
Stock Conc.(ng/mL)
Stock Aliquot(mL)
Volume Madeupto (mL)
Stock DilutionConc. (ng/mL)
Stock Dilution ID
1000000 1.5 5 300000AQ-H
300000 4 5 240000AQ-G
240000 2.5 5 120000AQ-F
120000 2.5 5 60000AQ-E
60000 2 5 24000AQ-D
24000 2 5 9600AQ-C
9600 2 5 3840AQ-B
3840 2 5 1536AQ-A
8/3/2019 Devanshu Final Ppt.1
16/45
Spiking of Dilutions in plasma for calibration curve standards
Transfer 0.2ml of each of above stock dilution of moxifloxacin into 10ml volumetric flask and
made up volume with plasma to achieve concentration ranging from 30.7 to 6000 ng/ml
Preparation of standard stock solution of Moxifloxacin for QC Weighed accurately 1 mg of Moxifloxacin working standard and transferred into a 1mL
volumetric flask. Dissolved in sufficient volume of methanol and made up to the volume with
the same to produce 1 mg/mL stock solution of Moxifloxacin. Stored in refrigerator below 10
C . The stock solution was diluted to suitable concentrations using diluent-1 for dilution for
spiking in plasma to obtain calibration quality control (QC) samples.
16
Preparation of spiked calibration curve standards:
Calibration Curve Standard (CC) Stock Dilution Conc. (ng/mL) Spiked CC Standard Conc. (ng/mL)
Std-H 300000 6000
Std-G 240000 4800
Std-F 120000 2400
Std-E 6000 1200
Std-D 24000 480
Std-C 9600 192
Std-B 3840 76.8
Std-A 1536.7 30.7
8/3/2019 Devanshu Final Ppt.1
17/45
Spiking of plasma for QC samples:
Transfer 0.2ml of each of above stock dilution of moxifloxacin in 10ml volumetric flask and
make up volume with plasma to achieve concentration in following table;
Preparation of moxifloxacin stock solutionfor QC
Amt. Weighed (mg) 1
Volume made up to (ml) 1
Potency (%) 99.8
Mol wt of compound 401.3
Free Mol wt of compound N/AP
Calculated stock conc.(ng/mL)
1000000
17
Table : Moxifloxacin stock dilutions for QC samples
Stock Conc. (ng/ml) Stock Aliquot (ml) Volume made up to(ml)
Final Conc. (ng/ml)
1000000 1.180 5 236000
236000 2.5 5 118000
118000 0.170 5 4012
4012 1.920 5 1540.6
Table : Spiking of plasma for QC samples of Moxifloxacin
Stock Conc. (ng/ml) Final Moxifloxacin conc. in spikedplasma (ng/ml)
Quality control (QC) standards
236000 4720HQC
118000 2360MQC
4012 80.2LQC
1540.6 30.8LOQQC
8/3/2019 Devanshu Final Ppt.1
18/45
Method Development
System Suitability test
System suitability test was performed every day before starting
any method validation exercise. System suitability test of the
LC-MS system was done by giving six injections of referencedilution and %CV for Drug and IS and there retention times
were calculated. The %CV for Drug and IS area ratio should be
within 4% and for retention time should be within 5%.
18
8/3/2019 Devanshu Final Ppt.1
19/45
Sr.no Moxifloxacin moxifloxacin-d4 Area ratio
Drug Area RT IS Area RT Drug/IS
1 65 0.465 37 0.451 1.7467
2 149243 0.461 101762 0.457 1.4666
3 144898 0.462 99488 0.458 1.4564
4 143113 0.438 98551 0.454 1.4522
5 143242 0.458 100199 0.454 1.4296
6 142652 0.456 95975 0.451 1.4863
7 138404 0.452 94780 0.448 1.4603
8 148 0.448 128 0.448 1.1504
Mean 143592.0 0.455 98459.2 0.452625 1.45857
SD 0.008799 0.003777 0.018552
%CV 1.933923 0.834528 1.30
Acceptance criteria:% CV of mean peak area
ratio
should be 4%% CV of the for retention
times ofdrug and IS
must be 5%
System suitability test
19
V lid ti t d
8/3/2019 Devanshu Final Ppt.1
20/45
Validation study Selectivity
Six lots of blank plasma were evaluated and an
interfering peak was observed at the retention time ofthe drug and at the retention time of the internal
standard. The interference at drug retention time in
blank matrix should be 20% of the mean peak area
response of drug in LOQ samples. The interference at ISretention time in blank matrix should be 5% of the
mean peak area response of IS in LOQ samples. The
%CV should be 20% for both drug and IS area in the
LOQ samples.
20
8/3/2019 Devanshu Final Ppt.1
21/45
Interference at RT of drug should be 20% of mean peak area
response in LOQ Samples
Interference at RT of IS should be 5% of mean peak area
response of IS in all plasma lots
Selectivity
Sr. No Plasma Lots Interferenceat RT of drug
LOQ Arearesponse
Interferenceat RT of Drug(as % of mean
LOQ)
Interferenceat RT of IS
IS Arearesponse
Interferenceat RT of IS( as % of
mean IS area)
1 BLK-01 250 2120 11.9 123 92762 0.14
2 BLK-02 47 1974 2.24 42 91054 0.05
3 BLK-03 96 2154 4.57 45 90552 0.05
4 BLK-04 58 2148 2.76 30 90605 0.03
5 BLK-05 28 2090 1.33 29 90473 0.03
6 BLK-06 11 2119 0.52 0 89990 0.00
Mean 2100.8 90894.3
SD 66.26 984.01
%CV 3.2 1.1
21
P i i d A
8/3/2019 Devanshu Final Ppt.1
22/45
Precision and Accuracy:
Precision and accuracy of the method was characterized by running three analytical batches;
each batch contained the following samples:
A reference standard solution (one sample, mixture with internal standard)
Blank matrix
Blank matrix with internal standard
Spiked calibration standards (1 set of 8 non-zero concentrations)
Limit of quantitative quality control (LOQQC) (6samples).
Lower quality control (LQC) (6 samples)
Middle quality control (MQC) (6 samples)
Higher quality control (HQC) (6 samples)
Precision:
The %CV at low , middle and high concentrations should be 15% and at LOQQC should be
20%.
Accuracy:
The mean conc. should be within 15% of the nominal conc. at low, middle, and high QC conc.
and should not deviate by more than 20% at LOQQC conc.
22
8/3/2019 Devanshu Final Ppt.1
23/45
23
Within batch precision & accuracy
S.NO LOQQC CONC. LQC CONC MQC CONC. HQC CONC.
1
32.6
75.3
2366.6
4726.5
2
31.0
81.2
2361.8
4721.4
3
31.8
78.4
2358.4
4718.2
4
31.2
69.8
2349.5
4707.2
5
32.2
79.2
2359.4 4719.8
6
31.9
79.3
2357.3 4717.9
Mean
31.78
77.2
2358.83 4718.5
S.D.(+/-) 0.601
4.401
5.640
6.359
C.V.(%)
1.89
5.70
0.23
0.13
Nominal Conc.
30.8
80.2
2360.0
4720.0
% Nominal
103.18
96.25
99.95
99.97
8/3/2019 Devanshu Final Ppt.1
24/45
24
Interbatch precision & accuracy
S.NO LOQQC CONC. LQC CONC MQC CONC. HQC CONC.
1 32.5 78.2 2449.1 4826.7
2 30.8 81.5 2448.9 4865.1
3 31.3 78.7 2396.3 4956.0
4 32.3 76.02 2380.7 4950.4
5 31.3 76.02 2459.5 4846.7
6 32.3 80.2 2413.5 4918.0
7 31.3 80.2 2389.7 4813.4
8 30.8 79.5 2399.7 4996.7
9 31.5 78.8 2369.9 4773.8
10 32.4 77.2 2424.1 4969.0
11 31.1 74.4 2380.1 5732.3
12 30.7 78.2 2369.2 4189.8
Mean 31.52 78.24 2406.72 4903.15
S.D. (+/-) 0.673 2.04 32.059 337.094
C.V. (%) 2.13 2.60 1.33 6.87
Nominal Conc. 30.8 80.2 2360.0 4720.0
% Nominal 102.33 97.55 101.97 103.88
8/3/2019 Devanshu Final Ppt.1
25/45
Linearity
The linearity of the method was determined by
regression analysis of standard plot associated with a
nine-point standard curve. The calibration curve was
plotted between concentration Vs. area ratio and wasshown to be linear from 30.7 ng/ml to 6000 ng/ml for
Moxifloxacin
25
8/3/2019 Devanshu Final Ppt.1
26/45
26
Statistical parameters for calibration curve of Moxifloxacin
Slope, y = 0.00364x + 0.00536
Correlation coefficient, r2 = 0.9991
8/3/2019 Devanshu Final Ppt.1
27/45
Recovery
The percentage recoveries for the drugs and the internal standard were determined by
comparing the peak areas of the response of drug extracted from plasma quality
control samples with that of the peak areas of the unextracted aqueous standard
samples containing the same concentration of the drug and the internal standard..The
recovery is deemed acceptable if C.V. is 20% for %recovery between low, middle
and high quality control concentrations.
The percent recoveries were calculated at each QC concentration by the following
equation.
% Recovery = Mean peak response of extracted samples X 100Mean peak response of non-extracted samples X C.F
C.F.= Concentration of extracted sample
Concentration of non extracted sample
27
8/3/2019 Devanshu Final Ppt.1
28/45
% Recovery
LQC-Response MQC-Response HQC-Response
S.No. ExtractedSamples UnextractedSamples ExtractedSamples UnextractedSamples ExtractedSamples UnextractedSamples
1 40410.00 51890.00 1394993.00 1958733.00 2494471.00 3442319.00
2 41562.00 54506.00 1374072.00 1908715.00 2730535.00 3396287.00
3 43541.00 56060.00 1460088.00 1948105.00 2661444.00 3477699.00
4 37643.00 55411.00 1386051.00 1940937.00 2628182.00 3552522.00
5 44527.00 58496.00 1411449.00 1941369.00 2683490.00 3548438.00
6 40607.00 57538.00 1382933.00 1872946.00 2770848.00 3592767.00
Mean 41381.67 55650.17 1401597.67 1928512.50 2661495.00 3501672.00
S.D. () 2453.99 2338.20 31335.35 31948.07 96140.68 75199.15
C.V.(%) 4.93 4.20 2.24 1.66 3.61 2.15
% Recovery
74.36
72.68 76.01
28
%Total Recovery of Moxifloxacin
8/3/2019 Devanshu Final Ppt.1
29/45
29
%Total Recovery of Moxifloxacin
Mean 74.36
S.D. () 1.66
C.V.(%) 2.23
% Recovery of Moxifloxacin d-4
S No.Extracted Samples
UnExtracted Samples
1 506373 6545302 476934 668119
3 521707 681840
4 511078 679482
5 516734 6813821
6 510843 686136Mean 507278.16 675238
S.D. () 15788.21 11805.66
C.V.(%) 3.11 1.75
% recovery 75.12
8/3/2019 Devanshu Final Ppt.1
30/45
Stability
Stock solution stability in solvent/solution
Prepared analyte and IS solution and keep aliquots stored at refrigeratedtemperature for specified time period, used as stability stock solution.
Prepared fresh analyte and IS stock solution and used as comparison stock
solution.
Injected six replicate from the vials of the stability stock solution and six
replicate from the vials of comparison stock solution.The %stability should be within range of 85-115%.
The % stability was calculated by the following equation:
% stability= Mean peak area response of stability samples X 100
Mean peak area response of comparison samples X C.F
C.F. = Concentration of stability sample
Concentration of comparison sample
30
8/3/2019 Devanshu Final Ppt.1
31/45
Stock Solution Stability of Moxifloxacin and Moxifloxacin-d4
S.No. Moxifloxacin Moxifloxacin-d4
Stability stock
Response
Comparison stock
Response
Stability stock
Response
Comparison stock
Response
1 1956733 1923470 683970 671938
2 1905715 1898756 669186 659465
3 1951105 1930876 681660 678438
4 1952937 1926768 681932 677378
5 1938639 1911560 681021 673468
6 1892946 1890678 666430 663762
Mean 1933012.50 1913684.67 677366.50 670741.50
S.D (+/-) 27089.19 16242.87 7520.20 7589.70
C.V. (%) 1.40 0.85 1.11 1.13
(%) Stability 101.00 99.98
31
8/3/2019 Devanshu Final Ppt.1
32/45
Short term stability
Prepared analyteand ISdilution from the standard stock solutions. Stored at room temperature for 6 to 24 hrs, used as stability dilutions.
Prepared fresh analyte and IS dilution used as comparison dilutions.
Inject 6 replicates of the stability dilutions from the same vial and 6 replicates
of the comparison dilutions from the same vial.
The %stability should be within range of 85-115%.
The % stability was calculated by the following equation:
% Stability = Mean peak area response of stability samples X 100
Mean peak area response of comparison samples
32
8/3/2019 Devanshu Final Ppt.1
33/45
Short term stability
33
Short term stability at room temperature for moxifloxacin and moxifloxacin-d4(IS)
Moxifloxacin Moxifloxacin d-4
S.No. Stability samples
Response
Comparison
samplesResponse
Stability samples
Response
Comparison
samplesResponse
1 535786 539872 548502 551166
2 535092 545413 553470 549400
3 547831 540310 561603 548597
4 544400 531698 558036 544905
5 529916 539053 546695 547416
6 535500 521061 550429 532383Mean 538095.3 536234.5 553122.5 545644.5
S.D (+/-) 6680.07 8635.33 5763.65 6824.37
C.V. (%) 1.24 1.61 1.04 1.25
(%) Stability 100.3 101.37
Freeze-thaw Stability
8/3/2019 Devanshu Final Ppt.1
34/45
Freeze-thaw Stability
Prepared 4 replicates of low and high conc. quality control samples and subject to 3
freeze thaw cycles, used as stability samples.
Each cycle consists of first freezing for at least 24hrs followed by unassisted
thawing at room temperature.
Prepared 4 replicates of fresh low and high conc. quality control samples, used as
comparison samples.
Inject the stability and comparison quality control samples. The %stability should be within range of 85-115%.
The % stability was calculated at each QC concentration by the following equation:
% Stability = Mean peak area response of stability samples X 100
Mean peak area response of comparison samples X C.F
34
Freeze thaw stability of Moxifloxacin in human plasma.
8/3/2019 Devanshu Final Ppt.1
35/45
35
Moxifloxacin Stability QC Moxifloxacin Comparison QC
S.No. LQC(ng/ml) HQC(ng/ml) LQC(ng/ml) HQC(ng/ml)
1 78.0 4849.0 77.0 4829.2
2 79.8 4746.8 79.1 4729.2
3 78.8 4794.4 79.6 4737.3
4 76.2 4901.5 79.3 4759.2
Mean 78.20 4822.93 78.75 4763.78
S.D (+/-) 1.523 66.989 1.185 45.402
C.V. (%) 1.9 1.4 1.5 1.0
NominalConc.
96.1 100.7 96.5 99.2
Mean with C.F. 78.56 4752.16
%Stability 99.5% 101.5%
B h t t bilit
8/3/2019 Devanshu Final Ppt.1
36/45
Bench top stability
Bench top stability in matrix
Prepared 4 replicates of low and high conc. quality control samples and stored at
room temperature, used as stability samples.
The storage period should exceed the duration for which the samples maintained
at room temperature in the intended study.
Following the storage period, prepared 4 replicates of fresh low and high conc.
quality control samples, used as comparison samples.
Inject the stability and comparison quality control samples.
The %stability should be within range of 85-115%.
The % stability was calculated at each QC concentration by the followingequation:
% Stability = Mean conc. of stability samples X 100
Mean conc. of comparison samples X C.F
36
Bench top Stability in matrix for Moxifloxacin
8/3/2019 Devanshu Final Ppt.1
37/45
37
Moxifloxacin Stability QC Moxifloxacin Comparison QC
S.NO LQC(ng/ml) HQC(ng/ml) LQC(ng/ml) HQC(ng/ml)
1 77.9 4770.6 77.0 4829.2
2 76.1 4844.9 79.1 4729.4
3 76.6 4770.2 79.6 4737.3
4 77.8 4751.7 79.3 4759.2
Mean 77.10 4784.35 78.75 4763.78
Mean with C.F 78.56 4752.16
S.D (+/-) 0.891 41.318 1.185 45.402
C.V. (%) 1.2 0.9 1.5 1
Nominal Conc. 94.7 99.9 96.5 99.2
% Stability 98.1 100.7
8/3/2019 Devanshu Final Ppt.1
38/45
Matrix Factor
A quantitativemeasure of the matrix effect due to suppression or enhancement of ionization
in a mass spectrometric detector is called as matrix factor.
Prepared reference mixture of analyte and internal standard at conc. representing 100%
extraction of analyte and internal standard at low, middle and high QC conc., used as
reference samples.
Processed 6 aliquots from 6 different blank plasma and reconstituted 2 aliquots each with
reference sample at low, middle and high QC conc., used as matrix samples.
Injected these 36 matrix samples along with 4 replicated of reference mixture at
LQC,MQC and HQC level. The %CV of matrix factor between low, middle and high QC
sample should be 15%.
The Matrix factor was calculated at each QC concentration by the following equation:
MF = Mean peak area ratio of matrix sample reconstituted with reference samples X 100
Mean peak area ratio of reference samples
38
8/3/2019 Devanshu Final Ppt.1
39/45
39
Matrix factor for Moxifloxacin and Moxifloxacin-d4
S.No LQC-Response MQC-Response HQC-Response
(area ratio) (area ratio) (area ratio)
MatrixSamples
ReferenceSamples
MatrixSamples
ReferenceSamples
MatrixSamples
ReferenceSamples
1 0.026 0.0265 0.968 1.0538 2.2061 2.177
2 0.0259 0.0268 1.0011 1.0274 1.9971 2.173
3 0.0266 0.0269 1.0234 1.0359 2.048 2.154
4 0.0246 0.0273 1.0163 1.0697 2.1013 2.117
Mean 0.025 0.026 1.002 1.046 2.043 2.155
S.D. () 0.0008 0.0003 0.0246 0.0188 0.0440 0.0270
C.V. (%) 3.3 1.2 2.5 1.8 2.2 1.3
Matrix factor of Moxifloxacin and Moxifloxacin-d4
8/3/2019 Devanshu Final Ppt.1
40/45
Matrix factor of Moxifloxacin and Moxifloxacin d4
Sample Matrix factor
LQC 1.0
MQC 1.0
HQC 0.9
Mean 0.95
S.D() 0.006
C.V(%) 0.6
40
R i j i R d ibili
8/3/2019 Devanshu Final Ppt.1
41/45
Reinjection Reproducibility
Any one of three PA batch analyzed and meeting the acceptance
criteria can be used for establishing re-injection reproducibity.
Re-injected all LOQ,MQC,HQC samples of the selected PA
batch. The % difference of 80% of all QC samples reinjected
should be within 15%.
Calculate the percentage difference for each quality controlsample by the following equation:
% Difference= Absolute (original value-Re-injected value) X100
original value
41
Reinjection Reproducibility
O i i l R i j t d % T t l f T t l f % f t t l f l
8/3/2019 Devanshu Final Ppt.1
42/45
42
Originalvalue
(ng/ml)
Re-injectedvalue
(ng/ml)
%Difference
Total no. ofsampleswhose %differenceare within
15%
Total no. ofsamplesanalysed
% of total no. of sampleswhose %difference are
within 15%
LQC
1 81.1 82.9 2.2 1.248131
2 82.5 79.9 3.2
3 81.5 82.4 1.1
4 77.0 77.8 1.0
5 79.7 81.0 1.6
6 80.2 82.0 2.2
MQC
1 2422.8 2473.0 2.1
2 2469.5 2461.4 0.3
3 2427.2 2455.1 1.1 18 18 100
4 2441.2 2407.1 1.4
5 2421.9 2461.4 1.6
8/3/2019 Devanshu Final Ppt.1
43/45
Conclusion
The developed method for estimation of Moxifloxacin was
validated according to USFDA guideline
All the results obtained were fulfilling the acceptance criteria
The developed method is rapid, sensitive, automated and
specificfor estimation of Moxifloxacin in human plasma.
The method is reliable and can be applied for bioequivalence or
pharmacokinetic study as well as therapeutic drug monitoring
43
8/3/2019 Devanshu Final Ppt.1
44/45
Key References:
Bressolle, F.; Bromet-pitit, M.; Audran, M. Validation of liquid
chromatography and gas chromatographic methods application
to pharmacokinetics,J. Chromatogr. B. 1996,686, 3-10.
Hartmann,C.; Smeyers-Verbeke, J.; Massart, D. L.; McDowall,
R. D. Validation of bioanalytical chromatographic methods, J.
Pharm. Biomed. Anal. 1998, 17 193-218.
US Food and Drug Administration, Guidance for industry-
Bioanalytical method validation, Center for Drug Evaluation
and Research, Rockville, MD, 2001. (Available at,
http://www.fda.gov/ ) http://www.drugbank.ca/drugs/DB00471
44
8/3/2019 Devanshu Final Ppt.1
45/45
45